Heron Therapeutics Q4 2023: oncology revenue $107.9M, ZYNRELEF record $5.6M, 2024 guidance reaffirmed

HERON THERAPEUTICS, INC. /DE/

Full-year 2023 oncology care franchise revenue $107.9M exceeded guidance; net product sales up 11% YoY.
ZYNRELEF Q4 net product sales record $5.6M (up from $3.9M Q4 2022); acute care franchise sales $6.1M.
Gross margin improved to 71% in Q4 from 58% a year ago; cash and equivalents $80.4M at year-end.
FDA approved expanded ZYNRELEF label covering ~13M annual procedures; CrossLink partnership adds up to 650 sales reps.
2024 guidance: product revenues $138-158M, adjusted EBITDA $(22)-$3M; VAN program PAS submission on track for Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

HERON THERAPEUTICS, INC. /DE/ updated its the three and twelve months ended December 31, 2023 guidance (reaffirmed).

Period: the three and twelve months ended December 31, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 12, 2024, Heron Therapeutics, Inc. (“Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023 (“Earnings Press Release”).

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-24-029926

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.